Механизмы действия, клинические аспекты и побочные эффекты антидепрессантов группы СИОЗС


https://doi.org/2618-6667-2018-77-123-133

Полный текст:


Аннотация

Цель: рассмотреть логические связи между нейробиологическими моделями, экспериментальными данными и клиническим применением СИОЗС при лечении тревожных и депрессивных расстройств. Метод: систематический обзор. Результаты: достижения экспериментальной нейробиологии являются основанием интерпретации различных вариантов поведения, ассоциированных с тревожными и депрессивными расстройствами. Особое внимание уделено нейробиологическим основам клинических и побочных эффектов антидепрессантов группы селективных ингибиторов обратного захвата серотонина (СИОЗС). Описаны кинические инструменты, которые бы позволили использовать рецепторные профили препаратов группы СИОЗС и данные доказательной медицины при назначении терапии. Вывод: приведенные данные могут служить рекомендациями для использования врачами в рутинной практике.


Об авторах

Виктория Анатольевна Вербенко
Медицинская академия имени С.И. Георгиевского, ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского», Симферополь
Россия
профессор


Александр Анатольевич Двирский
Медицинская академия имени С.И. Георгиевского, ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского», Симферополь
Россия
профессор


Список литературы

1. Jacob B.L., Azmita E.C. Structure and function of the brain serotonin system. Physiology Review. 1992;72(1):165–229. doi: 10.1152/ physrev.1992.72.1.165

2. Chinta S.J., Andersen J.K. Dopaminergic neurons. J. Biochem. Cell Biol. 2005;7(5):942–946. doi: 10.1016/j.biocel.2004.09.009

3. Martin P., Lemonnier F. The role of type 2 serotonin receptors, 5-HT2A and 5-HT2C, in depressive disorders: effect of medifoxamine. Encephale. 1994;7–8,20(4):427–435. PMID:7988407

4. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O’Laughlin I.A., Meltzer H.Y. 5-HT2A and D-2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001;76:1521–1531. PMID:11238736

5. Halberstadt A.L., Sindhunata I.S., Scheffers K., Flynn A.D., Sharp R.F., Geyer M.A., Young J.W. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology. 2016;107(8):364–375. doi: 10.1016/j.

6. Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdère P., Caccia S., Esposito E., Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 2002;26(3):311–324. doi: 10.1016/S0893-133X(01)00333-5

7. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 1993;14:262. PMID:8212321

8. Owens M., Knight D., Nemeroff C. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry. 2001;50:345–350. PMID:11543737

9. Celada P., Puig V., Amargós-Bosch M., Adell A., Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 2004;29(4):252–265. PMID:15309042

10. Gundlah C., Pecins-Thompson M., Schutzer W.E., Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Mol. Brain. Res. 1999;63:325–339. doi: 10.1016/ S0169-328X(98)00295-2

11. Tanaka E., North R.A. Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J. Neurophysiol. 1993;69:1749–1757. doi: 10.1101/lm.60803

12. Lindquist K.A., Wager T.D., Kober H. The brain basis of emotion: a meta-analytic review. Behav. Brain Sci. 2012;35(3):121–143. doi: 10.1017/S0140525X11000446

13. Araneda R., Andrade R. 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412. PMID:1851255

14. Rasanen P., Hakko H., Tiihonen J. Pindolol and major affective disorders: a three-year follow-up study of 30 485 patients. J. Clin. Psychopharmacol. 1999;19:297–302. PMID:10440455

15. Hansen R.A., Gartlehner G., Lohr K.N. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med. 2005;143(6):415–426. PMID:16172440

16. Mayo Clinic Staff. Antidepressants: Get tips to cope with side effects. Mayo Clinic Articles. 2016. 238 p.

17. Gareth J.S., Eamonn M.M. Quigley, constipation, IBS and the 5-HT4 receptor: What role for prucalopride? Clinical Medicine Insights. Gastroenterology. 2010;3:21–33. doi: 10.4137/CGast.S4136

18. Serretti A., Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 2009;29(3):259–266. doi: 10.1097/JCP.0b013e3181a5233f.

19. Kyoung-Uk L., Young Min L., Ji-Min N., Hae-Kook L., Yong-Sil K., Chung T.L., Tae-Youn J. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig. 2010;7(1):55–59. doi: 10.4306/pi.2010.7.1.55

20. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.I., Donahue R.M., Jamerson B.D., Metz A. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry. 2002;63(4):357–366. PMID:12000211

21. Herrera-Guzmán I., Herrera-Abarca J.E., Gudayol-Ferré E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010;177(3):323–329. doi: 10.1016/j.psychres.2010.03.006

22. Guay D. Hyponatremia associated with selective serotonin reuptake inhibitors: clinical review. Consult. Pharmacist. 2000;15:160–177.

23. Dalton S.O., Johansen C., Mellemkjaer L., Nørgård B., Sørensen H.T., Olsen J.H. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch. Intern. Med. 2003;163:59–64. PMID:12523917

24. Yuan Y., Tsoi K., Hunt R.H. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am. J. Med. 2006;119:719–727. doi: 10.1016/j.amjmed.2005.11.006

25. Montgomery S.A. Antidepressants and seizures: emphasis on newer agents and clinical implications. International Journal of Clinical Practice. 2005;59(12):1435–1440. doi: 10.1111/j.1368-5031.2005.00731.x

26. Skowron D.M., Stimmel G.L. Antidepressants and the risk of seizures. Pharmacotherapy. 1992;12(1):18–22. PMID:1549533

27. Hill T., Coupland C., Morriss R., Arthur A., Moore M., Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015;15:315. doi: 10.1186/s12888-015-0701

28. Maguire M.J., Weston J., Singh J., Marson A.G. Antidepressants for people with epilepsy and depression. Cochrane Database Syst. Rev. 2014;3(12): doi: 10.1002/14651858. CD010682.pub2.

29. He M., Deng C., Huang X.F. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain CNS Drugs. 2013;27(6):423–434. doi: 10.1007/s40263-013-0062-1

30. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treat- ments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998;18:10150–10156.

31. Schwartz T.L., Meszaros Z.S., Khan R., Nihalani N. How to control weight gain when prescribing antidepressants. Current Psychiatry. 2007;6(5):53–56.

32. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.J., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J. Perinatol. 2005;25:595–604. doi: 10.1038/sj.jp.7211352

33. Gadot Y., Koren G. The use of antidepressants in pregnancy: Focus on maternal risks. J. Obstet. Gynaecol. Can. 2015;37(1):56–63.

34. Palmsten K., Hernández-Díaz S., Huybrechts K.F., Williams P.L., Michels K.B., Achtyes E.D. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ. 2013;347:f4877. doi: https://doi.org/10.1136/ bmj.f4877

35. Boukhris T., Sheehy O., Mottron L., Bérard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2):117–124. doi: 10.1001/jamapediatrics.2015.3356

36. Nezvalová-Henriksen K., Spigset O., Brandlistuen R.E., Ystrom E., Koren G., Nordeng H. Effect of prenatal selective serotonin reuptake inhibitor (SSRI) exposure on birthweight and gestational age: a sibling-controlled cohort study. In. J. Epidemiol. 2016;(5):2018–2029. doi: 10.1093/ije/dyw049

37. Brown A.S., Gyllenberg D., Malm H., McKeague I.W., Hinkka-Yli-Salomäki S., Artama M., Gissler M., Cheslack-Postava K., Weissman M.M., Gingrich J.A., Sourander A. Association of selective serotonin reuptake inhibitor exposure during pregnancy with speech, scholastic, and motor disorders in Offspring. JAMA Psychi- atry. 2016;73(11):1163–1170. doi: 10.1001/jamapsychiatry.2016.2594

38. Clements C.C., Castro V.M., Blumenthal S.R., Rosenfield H.R., Murphy S.N., Fava M., Erb J.L., Churchill S.E., Kaimal A.J., Doyle A.E., Robinson E.B., Smoller J.W., Kohane I.S., Perlis R.H. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Molecular Psychiatry. 2015;20:727–734. doi: 10.1038/ mp.2014.90

39. Shonkoff J.P., Boyce W.T., McEwen B.S. Neuroscience, molecular biology, and the childhood roots of health disparities: building a new framework for health promotion and disease prevention. JAMA. 2009;30(21):2252–2259.

40. Schatzberg A., Haddad P., Kaplan E., Lejoyeux M., Rosenbaum J., Young, A. et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Journal of Clinical Psychiatry. 1997;58(7):5–10.

41. Levi-Montalcini R., Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 1951;116(2):321–361.

42. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549–553.

43. Timmusk T., Palm K., Metsis M., Reintam T., Paalme V., Saarma M., Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 1993;Mar;10(3):475–489.

44. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors. Author manuscript; available in PMC 2008 Aug 9. Published in final edited form as. Growth Factors. 2004;22(3):123– 131. doi: 10.1080/08977190410001723308

45. Leal G., Afonso P.M., Salazar I.L., Duarte C.B. Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 2015;1621:82–101. doi: 10.1016/j.brainres.2014.10.019

46. Lee B.H., Kim Y.K. The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig. 2010;7(4):231–235. doi: 10.4306/pi.2010.7.4.231

47. Björkholm C., Monteggia L.M. BDNF — a key transducer of antidepressant effects. Neuropharmacology. 2016;102(3):72–79. doi: 10.1016/j.neuropharm.2015.10.034

48. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology. 2008;33(1):73–83. doi: 10.1038/sj.npp.1301571

49. Yu H., Chen Z.Y. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol. Sin. 2011;32(1):3–11. doi: 10.1038/aps.2010.184. Epub 2010 Dec 6

50. Bonne O., Gill J.M., Luckenbaugh D.A., Collins C., Owens M.J., Alesci S., Neumeister A., Yuan P., Kinkead B., Manji H.K., Charney D.S., Vythilingam M. Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the cerebrospinal fluid of civilians with posttrau- matic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry. 2011;72(8):1124–1128. doi: 10.4088/JCP.09m05106blu

51. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006;398:215–219. doi: 10.1016/j.neulet.2005.12.085

52. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr. Res. 2006;86:321–322. doi: 10.1016/j.schres.2006.05.028

53. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Ku- makiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry. 2003;54(1):70–75. doi: 10.1016/S0006-3223(03)00181-1

54. Lamego M.K., de Souza Moura A.M., Paes F., Ferreira Rocha N.B., de Sá Filho A.S., Lattari E., Rimes R., Manochio J., Budde H., Wegner M., Mura G., Arias-Carrión O., Yuan T.F., Nardi A.E., Machado S. Aerobic exercise does not predict brain derived neurotrophic factor and cortisol alterations in depressed patients. CNS Neurol. Disord. Drug Targets. 2015;14(9):1116–1128. doi: 10.2174/187152731566615 1111125402.

55. Rethorst C.D., Greer T.L., Toups M.S., Bernstein I., Carmody T.J., Trivedi M.H. IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. Transl. Psychiatry. 2015;5:e611. doi: 10.1038/tp.2015.104

56. Giese M., Unternährer E., Hüttig H., Beck J., Brand S., Calabrese P., Holsboer-Trachsler E., Eckert A. BDNF: An indicator of insomnia? Mol. Psychiatry. 2014;19(2):151–152. doi: 10.1038/mp.2013.10

57. Martinotti G., Pettorruso M., De Berardis D., Varasano P.A., Lucidi Pressanti G., De Remigis V., Valchera A., Ricci V., Di Nicola M., Janiri L., Biggio G., Di Giannantonio M. Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms. Int. J. Neuropsychopharmacol. 2016;19(5):1093. pyw003. doi: 10.1093/ijnp/pyw003.


Дополнительные файлы

Для цитирования: Вербенко В.А., Двирский А.А. Механизмы действия, клинические аспекты и побочные эффекты антидепрессантов группы СИОЗС. Психиатрия. 2018;1(77):123-133. https://doi.org/2618-6667-2018-77-123-133

For citation: Verbenko V., Dvirsky A. The SSRI antidepressants: clinical aspects, new side effects and mechanisms of actions. Psychiatry. 2018;1(77):123-133. (In Russ.) https://doi.org/2618-6667-2018-77-123-133

Просмотров: 46

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1683-8319 (Print)